Description

PRODUCT OVERVIEW

A Modified Peptide for Laboratory Characterization

CJC-1295 Without DAC is described as a modified GHRH analogue investigated in the context of peptide structure and growth hormone-related signaling research.

The absence of the Drug Affinity Complex (DAC) modification distinguishes this form from CJC-1295 with DAC. This structural difference is important when comparing research materials, evaluating analytical results, and reviewing scientific literature.

Available evidence for the non-DAC form remains limited. Its identity and properties should be assessed using compound-specific documentation rather than assumptions based on similarly named materials.

PRODUCT SPECIFICATIONS

Confirm the exact molecular identity, peptide sequence, and chemical form against the supplier’s specifications and applicable Certificate of Analysis (COA).

SCIENTIFIC BACKGROUND

CJC-1295-related compounds are synthetic analogues of growth hormone-releasing hormone. The DAC-modified form incorporates an additional structural component designed to facilitate binding to serum albumin, distinguishing it from the non-DAC form.

The U.S. Food and Drug Administration’s 2024 review identified substantial gaps in the characterization and pharmacological evidence available for CJC-1295 free base and acetate. Findings reported for DAC-modified material do not independently establish the properties or activity of the non-DAC form.

For laboratory evaluation, the precise molecular structure, chemical form, and analytical documentation are therefore important considerations.

RESEARCH APPLICATIONS

CJC-1295 Without DAC may be examined in controlled laboratory settings for:

• Peptide Identification: Evaluation of reported molecular identity and structural characteristics.
• Analytical Characterization: Examination of composition and analytical properties using appropriate laboratory methods.
• GHRH-Related Research: Scientific investigation involving GHRH analogue structures and related research questions.
• Comparative Peptide Analysis: Assessment of structural differences between documented peptide forms.
• Documentation Review: Comparison of product specifications, batch identifiers, and available analytical findings.

These applications describe potential areas of laboratory investigation and do not establish biological activity, clinical effectiveness, or safety for a particular product.

QUALITY & LABORATORY DOCUMENTATION

Products are supported by applicable third-party laboratory testing documentation. Independent verification and additional testing may be conducted where appropriate.

Researchers should review the applicable documentation for reported identity, purity, analytical methods, testing dates, laboratory information, and batch identification, where available. Documentation should correspond to the specific product and lot being evaluated.

LOT & BATCH REFERENCE

Product-specific batch information should be reviewed alongside the corresponding laboratory documentation. Where a lot number or batch identifier is provided, retain it with the associated analytical records to support traceability and technical review.

STORAGE & HANDLING

Store and handle the material according to its supplier-provided specifications and applicable laboratory procedures. Follow the product-specific documentation for storage conditions, packaging requirements, and handling precautions.

RESEARCH USE STATEMENT

CJC-1295 Without DAC is offered strictly for laboratory and scientific research purposes. It is not intended for human or veterinary use, consumption, diagnosis, treatment, or prevention of any disease.

IMPORTANT NOTICE

Product names and commercial descriptions alone do not establish molecular identity, purity, or biological activity. Review the applicable product specifications and lot documentation before using the material in a research setting. No claim is made that this product is approved for human use or has established clinical benefits.